ANALYSTS GIVE AVERAGE RATING OF “BUY” TO PFIZER INC. (PFE)
Shares of Pfizer Inc. (NYSE:PFE) have received an average recommendation of “Buy” from the twenty-five brokerages that are currently covering the firm. Thirteen analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $37.67.

A number of equities analysts have commented on the stock. Argus reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a report on Sunday, August 28th. BMO Capital Markets set a $33.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a report on Wednesday, November 30th. Sanford C. Bernstein reaffirmed an “overweight” rating on shares of Pfizer in a report on Wednesday. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, December 2nd. They issued a “neutral” rating for the company. Finally, Jefferies Group set a $34.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Friday, November 11th.

Pfizer (NYSE:PFE) opened at 31.70 on Tuesday. The stock has a 50 day moving average of $31.62 and a 200-day moving average of $34.02. The stock has a market cap of $192.37 billion, a P/E ratio of 31.83 and a beta of 0.91. Pfizer has a one year low of $28.25 and a one year high of $37.39.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The company had revenue of $13.05 billion for the quarter, compared to analyst estimates of $13.05 billion. During the same period in the previous year, the business posted $0.60 EPS. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. Analysts anticipate that Pfizer will post $2.42 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 1st. Shareholders of record on Friday, November 11th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.79%. Pfizer’s dividend payout ratio (DPR) is presently 106.20%.

In other Pfizer news, insider Albert Bourla sold 18,390 shares of Pfizer stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now owns 149,199 shares of the company’s stock, valued at approximately $4,483,429.95. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Maddaluna sold 10,000 shares of Pfizer stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares in the company, valued at approximately $3,698,871. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in PFE. First Hawaiian Bank boosted its stake in shares of Pfizer by 0.3% in the third quarter. First Hawaiian Bank now owns 8,585 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 24 shares during the last quarter. Ronna Sue Cohen boosted its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares during the last quarter. Alpha Windward LLC boosted its stake in shares of Pfizer by 0.5% in the third quarter. Alpha Windward LLC now owns 8,315 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 40 shares during the last quarter. New York Life Trust Co. boosted its stake in shares of Pfizer by 0.5% in the third quarter. New York Life Trust Co. now owns 9,062 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 42 shares during the last quarter. Finally, Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares during the last quarter. 68.53% of the stock is currently owned by institutional investors.